Introduction {#sec2}
============

Endometriosis is a chronic gynaecological disorder characterized by the presence of endometrial-like tissue outside the uterus ([@ref13]). Symptoms of endometriosis often include dysmenorrhea (pain with periods), non-menstrual pelvic pain, and infertility ([@ref13]; [@ref3]). Epidemiological studies suggest an estimated prevalence of 2--10% in women within the reproductive age range overall ([@ref12]) and a prevalence as high as 20--30% in women suffering from infertility ([@ref42]). The gold standard of diagnosis is laparoscopy, which is an invasive method and thus only indicated in women with relevant symptoms. The prevalence of asymptomatic endometriosis therefore remains unknown. The main treatment methods of endometriosis include surgical removal of ectopic tissue and/or hormonal treatment to suppress ovarian function with adverse side effects ([@ref55]). The aetiology of endometriosis is complex and under-explored, yet abnormalities in the immune system of women with endometriosis have been consistently demonstrated and may reflect the chronic inflammatory response to the presence of ectopic endometrium. In addition, these abnormalities may imply that the pre-disease milieu was supportive for adherence, survival, and maintenance of these ectopic endometrial tissues ([@ref4]; [@ref11]; [@ref24]; [@ref25]). Thus, a hypothesis was formed that women affected by endometriosis have an immunity-associated disorder, and such an association between endometriosis and autoimmune diseases has been proposed by several studies ([@ref50]; [@ref10]; [@ref11]; [@ref27]).

Robust quantification of the association between endometriosis and autoimmune diseases could facilitate understanding of the causes and consequences of both disorders, especially on the question of whether endometriosis is associated with immunological disorders. Also, considering the current medication for endometriosis is mainly hormonal treatment with considerable side effects due to interference with oestrogen levels, such evidence could help to provide reference for better healthcare practices through the discovery of novel drug targets, such as immuno-modulators, and development of new diagnostic tools for endometriosis. Therefore, we conducted a systematic review of published studies that investigated the association between endometriosis and autoimmune diseases, by applying methods that rank the quality of evidence and by summarizing to inform scientific discovery and clinical practice.

Methods {#sec3}
=======

Search strategy {#sec4}
---------------

This systematic review was registered and accepted for inclusion in PROSPERO ([@ref49]) in December 2017 (PROSPERO ID Number: CRD42017084175).

A protocol-driven systematic search for articles reporting on an association between endometriosis and autoimmune disease was conducted using the MEDLINE (via OVID), Embase (via OVID), Web of Science Core Collection (Indexes = SCI-Expanded, SSCI, ESCI, CPCI-S, CPCI-SSH), and CINAHL (via EbscoHost) databases. Each database was searched from the database inception date until 7 April 2018. Search terms included a combination of database-specific controlled vocabulary terms and free-text terms relating to endometriosis (e.g. 'endometrio^\*^') and autoimmune diseases (e.g. 'autoimmune diseas^\*^', 'autoimmune response', 'autoimmunit^\*^', 'autoantibod^\*^'). To capture other potentially relevant articles, we also combined search terms representing endometriosis with search terms for 23 autoimmune diseases (i.e. Addison's disease, autoimmune hepatitis, antiphospholipid syndrome, alopecia areata, coeliac disease (CLD), Crohn's disease (CD), dermatitis herpetiformis, Graves' disease, Hashimoto's autoimmune thyroiditis, immune thrombocytopenic purpura, Kawasaki disease, multiple sclerosis (MS), narcolepsy, pernicious anemia, primary biliary cirrhosis, rheumatoid arthritis (RA), rheumatic fever, scleroderma, Sjögren's syndrome (SS), systemic lupus erythematosus (SLE), temporal arteritis, type 1 diabetes, ulcerative colitis (UC), vitiligo) that were reported to be most prevalent (i.e. with a worldwide prevalence rate ≥10 per 100 000 based on a review ([@ref22]) that included a comprehensive list of autoimmune diseases). To be as comprehensive as possible, the search was not restricted to any study types. An example search strategy for the MEDLINE database is described in [Supplementary Material, Table I](#sup1){ref-type="supplementary-material"}.

Inclusion criteria and study selection {#sec5}
--------------------------------------

Study inclusion criteria comprised peer-reviewed publications with population-based studies that reported an association between endometriosis and any type of autoimmune diseases. Case reports and case series were excluded as their sampling from among, and thus representation of, the larger populations is unknown. Review papers, meta-analysis, organizational guidelines, editorial letters, and expert opinions were excluded in order to avoid duplication and erroneous weighting towards more frequently cited or discussed publications. Conference abstracts were also excluded as their full study reports were not obtainable to be assessed and their scientific rigor had not been peer-reviewed. Moreover, only studies published in English language journals were included.

All articles identified by searching the four databases were imported into Mendeley for screening. There were two rounds of screening for study inclusion. In the first round, two reviewers (N.S. and Q.F.) performed screening separately by reviewing titles, abstracts, and key terms for relevance of both endometriosis and autoimmune diseases. In the second round of screening, full texts of the articles identified during the initial screening were retrieved and read in detail to assess for eligibility. Possible discordance during study selections were discussed with a third reviewer (N.R.) to reach a consensus.

Data extraction {#sec6}
---------------

Data from the included studies were extracted into a standard form, detailing the author(s), publication year, country, time of study conduct, study design, ascertainment method of diseases and control or comparison group selection, number of study participants, reported risk estimates of endometriosis in association with autoimmune diseases, any adjustment for confounding factors in generating the effect estimates, and any measures taken in addressing temporality for diagnosis of endometriosis and autoimmune diseases. When effect estimates for association between endometriosis and autoimmune diseases were not listed in the original article but enough information was available, their effect estimates were calculated by Review Manager software Version 5.3. Also, where the listed effect estimates in the original article were presented with enough information to be recalculated, such effect estimates were calculated again by RevMan to check for accuracy of the original report.

Quality assessment {#sec7}
------------------

Quality assessment was performed based on GRADE criteria ([@ref17]) and carried out separately by two reviewers independently (N.S. and M.K.). Guided by the Cochrane group ([@ref43]), the quality of evidence was assessed for each study outcome of interest (any reported autoimmune diseases in association with endometriosis by at least three studies) based on study design and factors that could reduce the quality of evidence (risk of bias, inadequacy or inaccuracy of statistical analyses, inconsistency of results, indirectness, imprecision, publication bias) as well as factors that could increase the quality of evidence (population size, number of outcome events, adjustment for potential confounders, temporality of diagnosis). Any discordance during the assessment of the quality of evidence was discussed with a third reviewer (C.B.) to reach consensus.

Data synthesis and meta-analysis {#sec8}
--------------------------------

Meta-analyses were performed for each autoimmune disease reported to be associated with endometriosis by at least three studies and were also stratified by study design (cross-sectional, case--control, or cohort studies) for each outcome. For cross-sectional and case--control studies, raw data from each study were extracted to calculate a Mantel--Haenszel odds ratio (OR) with 95% CIs (hence, the ORs displayed in the meta-analysis figures and in the study characteristics tables differ slightly). For cohort studies, an inverse variance probability weighted model was used to pool study results to calculate a rate ratio (RR) with 95% CIs. As almost all of the cohort studies had adjusted for potential confounding variables (albeit not consistent covariates among them), pooling raw data was not possible. Statistical heterogeneity among studies for each outcome was assessed by inspecting the study-specific magnitudes of effect and the heterogeneity (*I^2^*) statistics. The *I^2^* statistics for heterogeneity in meta-analysis was interpreted based on the GRADE approach recommended by Cochrane group ([@ref47]). In meta-analyses of multiple studies for a specific outcome, a fixed-effect estimate was calculated if *I^2^* heterogeneity = 0%; however, if *I^2^* heterogeneity ≥0% in the meta-analysis, a random-effect estimate and a fixed-effect estimate were both calculated for sensitivity analysis.

Forest plots were constructed to present risk estimates and meta-analysis results for each autoimmune disease reported by at least three studies to be associated with endometriosis.

In meta-analyses of cohort studies, hazard ratio (HR) and standardized incidence ratio (SIR) were treated as equal to the rate ratio or relative risk.

In addition, for study results that did not explicitly specify the type of autoimmune disease but instead used broad terms such as 'rheumatic disease', 'arthritis', 'colitis', or 'autoimmune diseases', their study results and risk estimates were presented in the data extraction characteristics form, but they were not included in the meta-analysis or forest plots.

A sensitivity analysis was performed for the meta-analyses by taking out each study one at a time from the meta-analysis and recalculating the pooled effect size and *I^2^* to assess for the influence of each study on the pooled effect size, if there were at least three studies included in the meta-analysis.

Results {#sec9}
=======

Study selection {#sec10}
---------------

The initial search retrieved 653 results from MEDLINE, 1543 from Embase, 49 from CINAHL, and 732 from Web of Science Core Collection. All articles identified in the four databases were imported into Mendeley for screening. After removing duplicates, there were 2070 papers uploaded to Mendeley for first-stage screening. After the first-stage screening by reviewing titles, abstracts, and key terms related to endometriosis or autoimmune diseases, 1948 publications were excluded for not addressing both endometriosis and autoimmune diseases and 122 articles were identified to be potentially relevant and then assessed for eligibility. After the first round, 96 articles were excluded for not investigating an association between endometriosis and autoimmune diseases at a population-level (*n* = 77) or for being a review article or meta-analysis (*n* = 8), a conference abstract (*n* = 10), an expert opinion (*n* = 1), or a case report (*n* = 1). Finally, 26 articles met all the inclusion criteria and were included in this review, 14 of which were included for quantitative synthesis for having calculable risk estimates ([Fig. 1](#f1){ref-type="fig"}).

![**Flow chart for study inclusion and exclusion process**.](dmz014f1){#f1}

Study characteristics {#sec11}
---------------------

Detailed description of key characteristics for the 26 included studies is shown in [Tables I](#TB1){ref-type="table"}--[IV](#TB4){ref-type="table"}. Briefly, 8 (30.8%) studies were implemented in the population in North America, 12 (46.2%) were in Europe, 3 (11.5%) were in South America, and 3 were (11.5%) in Asia ([Table I](#TB1){ref-type="table"}). With regard to study design, 6 (37.5%) studies were cross-sectional, 12 (46.2%) were case--control studies, and 6 (37.5%) were cohort studies (including 4 prospective cohort studies and 2 retrospective cohort studies), while 2 (7.7%) studies did not generate risk estimates for an association between endometriosis and autoimmune diseases, but instead compared clinical manifestations and serum autoantibody test results for endometriosis and SLE ([@ref39]) or treatment methods and serum autoantibody test results for endometriosis and inflammatory bowel disease (IBD) ([@ref29]).

###### 

**Characteristics of included studies (part 1)**.

  **Citation**   **Country**   **Study period**   **Study design**                                          **Endometriosis ascertainment and number**
  -------------- ------------- ------------------ --------------------------------------------------------- ----------------------------------------------------------------------------------------------------
  [@ref16]       USA           1973--1982         Case--control study                                       Hospital diagnosis (*n* = 12)
  [@ref28]       USA           Not specified      Case--control study                                       Self-reports (*n* = 43)
  [@ref51]       USA           1988--1989         Case--control study                                       Hospital diagnosis with hysterectomy (*n* = 22)
  [@ref50]       USA, Canada   1998               Cross-sectional study                                     Self-reports of laparoscopy/laparotomy (*n* = 3680)
  [@ref34]       USA           1986--1997         Prospective cohort study; 11 years follow-up              Self-reports (*n* = 155)
  [@ref41]       Belgium       1999--2000         Case--control study                                       Hospital diagnosis (*n* = 21)
  [@ref18]       Norway        Not specified      Case--control study                                       Self-reports (*n* = 7)
  [@ref39]       Brazil        Not specified      Cross-sectional study                                     Laparoscopy with histological analysis (*n* = 45 including 13 stage I/II and 32 stage III/IV)
  [@ref40]       Brazil        2005--2006         Case--control study (reported as cross-sectional study)   Surgical and histological diagnosis (*n* = 148)
  [@ref10]       Denmark       2001               Cross-sectional study                                     Hospital diagnosis (prevalence: 4.91 per 1000 population)
  [@ref31]       Spain         1990--2004         Case--control study                                       Surgical with histological diagnosis (*n* = 342)
  [@ref1]        Brazil        2000--2003         Case--control study                                       Laparoscopy with histological diagnosis ≤6 months before blood collection (*n* = 120)
  [@ref15]       USA           1998               Cross-sectional study                                     Self-reports of surgical diagnosis (*n* = 4331)
  [@ref52]       Sweden        1969--2008         Retrospective cohort study; 5 years follow-up             Hospital diagnosis (*n* = 517)
  [@ref35]       Denmark       1977--2007         Retrospective cohort study; 1 year follow-up              Hospital diagnosis (*n* = 37 661)
  [@ref26]       Denmark       1977--2007         Retrospective cohort study; 13 years follow-up            Hospital diagnosis (*n* = 37 661)
  [@ref45]       Italy         2012               Case--control study                                       Laparoscopy with histological diagnosis (*n* = 223)
  [@ref56]       Italy         2009--2013         Case--control study                                       Hospital diagnosis (*n* = 304)
  [@ref20]       USA           1989--2011         Prospective cohort study; 22 years follow-up              Self-reports of laparoscopy with hospital records checked in part of the participants (*n* = 6434)
  [@ref21]       Sweden        1964--2011         Case--control study                                       Hospital diagnosis (*n* = 371)
  [@ref54]       Korea         2009--2011         Cross-sectional study                                     Hospital diagnosis (*n* = 5615)
  [@ref23]       Taiwan        2000--2010         Cross-sectional study (rheumatoid disease)                Hospital diagnosis (*n* = 27 973)
  [@ref29]       USA           Not specified      Case--control study                                       Hospital diagnosis (*n* = 51)
  [@ref6]        Netherlands   2002--2010         Cross-sectional study                                     Hospital diagnosis (*n* = 4) and self-reports (*n* = 1)
  [@ref53]       Taiwan        2001--2006         Case--control study (SS)                                  Hospital diagnosis (*n* = 9191)
  [@ref38]       Denmark       1994--2015         Case--control study (IBD)                                 Hospital diagnosis (*n* = 297 in IBD cohort vs. *n* = 18 708 in IBD-free cohort)

SS, Sjögren's syndrome; IBD, inflammatory bowel disease.

###### 

**Characteristics of included studies (part 2)**.

  **Citation**   **Autoimmune disease ascertainment and number**                                                    **Control selection and number**
  -------------- -------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------
  [@ref16]       Hospital diagnosis: SLE (*n* = 109)                                                                SLE-free women from the same hospital excluding those admitted for obstetric/gynaecologic conditions (*n* = 109)
  [@ref28]       Self-reports: RA (*n* = 1)                                                                         Friend control: self-reported ENDO-free (*n* = 43)
  [@ref51]       Hospital diagnosis: hysterectomy: SLE (*n* = 2); AD other than SLE (*n* = 12); any AD (*n* = 14)   Women diagnosed with fibroids by hysterectomy (*n* = 185)
  [@ref50]       Self-reports of hospital diagnosis: SLE (*n* = 31); MS (*n* = 19); RA (*n* = 68); SS (*n* = 23)    Literature statistics: US general female population
  [@ref34]       Physician diagnosis: RA (*n* = 158)                                                                Women without RA (*n* = 31 178)
  [@ref41]       Serological test: TPO positive (*n* = 6)                                                           Randomly selected, age-matched parous women (*n* = 100)
  [@ref18]       Hospital diagnosis: SS (*n* = 47)                                                                  Healthy control matched on age, region (*n* = 142)
  [@ref39]       Hospital diagnosis: SLE (*n* = 15)                                                                 Healthy women from the same clinical centre underwent laparoscopy (*n* = 21)
  [@ref40]       Self-reports (hospital diagnosis validated partly) ATD (*n* = 38)                                  Women without ENDO from a family planning clinic (*n* = 158)
  [@ref10]       National registry, hospital diagnosis                                                              National registry: Danish general population
  [@ref31]       Hospital diagnosis: SLE (*n* = 120), SS (*n* = 22)                                                 Asymptomatic women attending gynaecology clinic in the same hospital as the cases (*n* = 501)
  [@ref1]        Blood test: CLD (*n* = 17); biopsy: CLD (*n* = 13)                                                 Healthy female donated blood in the same city (*n* = 1500)
  [@ref15]       Self-reports: Addison's disease (*n* = 10)                                                         Literature statistics: US general female population
  [@ref52]       CLD biopsy (*n* = 11 097)                                                                          National registry: matched on age, county, calendar period (*n* = 54 992)
  [@ref35]       Hospital diagnosis in ENDO cohort; SLE (*n* = 54), SS (*n* = 86), MS (*n* = 130)                   National registry: Danish general female population (age-/period-specific incident rate)
  [@ref26]       Hospital diagnosis in ENDO cohort; UC (*n* = 228), CD (*n* = 92), IBD (*n* = 320)                  National registry: Danish general female population (age-/period-specific incidence rate)
  [@ref45]       Serological and histological diagnosis: CLD (*n* = 7); self-reports of ADs (*n* = 37)              Female nurses with no known ENDO (*n* = 246)
  [@ref56]       Self-reports (?weren't mention): AD (*n* = 41)                                                     Female patient from the same hospital with no known ENDO or immune dysfunction (*n* = 318)
  [@ref20]       Self-reports confirmed by physician diagnosis: SLE (*n* = 103), RA (*n* = 390)                     Female nurses responded to the survey with no known ENDO (*n* = 108 019)
  [@ref21]       Hospital diagnosis: SLE (*n* = 2834)                                                               National registry: female controls matched on birth year, sex, county (*n* = 14 164)
  [@ref54]       Hospital diagnosis: Graves's disease (*n* = 105); ATD (*n* = 159)                                  National registry: general female population matched on age, sampling year, sampling weight (*n* = 22 460)
  [@ref23]       Hospital diagnosis: rheumatic disease (*n* = 2891)                                                 Nationwide registry: general female population (*n* = 27 937)
  [@ref29]       Hospital diagnosis: CD (*n* = 82), UC (*n* = 71)                                                   Women with IBD but without ENDO (*n* = 102) matched on age, IBD type
  [@ref6]        Hospital diagnosis: RA (*n* = 178)                                                                 Literature statistics: Dutch general females
  [@ref53]       Hospital diagnosis: SS (*n* = 301)                                                                 Nationwide registry: female controls matched on age, income, geographic location, first diagnosis year of ENDO (*n* = 27 573)
  [@ref38]       Hospital diagnosis: UC (*n* = 7548), CD (*n* = 6731), IBD (*n* = 14 279)                           Nationwide registry: women without IBD at conception (*n* = 1 832 732)

AD, autoimmune disease; ATD, autoimmune thyroid disorder; ENDO, endometriosis; SS, Sjögren's syndrome; RA, rheumatoid arthritis; TPO, thyroid peroxidase antibody; CLD, coeliac disease; MS, multiple sclerosis; IBD, inflammatory bowel disease; CD, Crohn's disease; UC, ulcerative colitis.

###### 

**Characteristics of included studies (part 3)**.

  **Citation**   **Risk estimates (in original reports)**                                                                                                                                                                                                                         **Risk estimates (calculated/with correction)**
  -------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@ref16]       SLE: OR = 2.0 (0.6--6.8)                                                                                                                                                                                                                                         
  [@ref28]       RA: RR = 1.00                                                                                                                                                                                                                                                    RA: OR = 3.07 (0.12, 77.50)
  [@ref51]       SLE prevalence was too low to generate ORs                                                                                                                                                                                                                       SLE prevalence: 9.09% vs. 0% in women with ENDO vs. fibroids; ADs other than SLE: OR = 0.75 (0.09, 6.13); any AIDs: OR = 2.50 (0.64, 9.75)
  [@ref50]       SLE: POR = 20.7 (14.3--29.9)[^\*^](#tblfn1){ref-type="table-fn"}; MS: POR = 7.1 (4.4--11.3)[^\*^](#tblfn1){ref-type="table-fn"}; RA: POR = 1.5 (1.2--1.9)[^\*^](#tblfn1){ref-type="table-fn"}; SS: POR = 23.9 (15.5--36.5)[^\*^](#tblfn1){ref-type="table-fn"}   
  [@ref34]       Multivariate-adjusted; RA: RR = 1.59 (0.82--3.08) all women; RA: RR = 1.48 (0.71-3.07) ever pregnant women                                                                                                                                                       
  [@ref41]       TPO-Abs positive: RR = 3.57 (1.09--11.8)[^\*^](#tblfn1){ref-type="table-fn"}                                                                                                                                                                                     OR = 4.60 (1.40, 15.13)
  [@ref18]       ---                                                                                                                                                                                                                                                              OR = 4.31 (0.93, 20.01)
  [@ref39]       Musculoskeletal manifestations, mucocutaneous, manifestations and antibodies                                                                                                                                                                                     
  [@ref40]       ATD: OR = 0.52 (0.25--1.06)                                                                                                                                                                                                                                      ATD: OR = 0.51 (0.25--1.04)
  [@ref10]       Pairwise ORs of ENDO with type 1 diabetes: 1.0; CLD: 1.6; pernicious anemia: 1.1; purpura: 1.9; MS: 1.3; Gulian Barre syndrome: 1.3; CD: 1.5; UC: 1.4; primary biliary cirrhosis: 2.0; psoriasis: 1.3; vitiligo: 2.2; scleroderma: 1.5; SLE: 1.6; SS: 1.6        
  [@ref31]       OR for SLE in women with ENDO history: 0.37 (0.09--1.59); OR for ENDO in SLE history: 2.9 (0.27--32.57); OR for SS in ENDO history: 2.17 (0.48--9.90)                                                                                                            ENDO risk in SLE vs. non-SLE: OR = 2.94 (0.27--32.56); SS risk in ENDO vs. non-ENDO: OR = 2.18 (0.48, 9.91)
  [@ref1]        Positive serology indicative for CLD: OR = 5.4 (1.8--15.5)[^\*^](#tblfn1){ref-type="table-fn"}; Biopsy-confirmed CLD: OR = 3.8 (1.0--14.1)[^\*^](#tblfn1){ref-type="table-fn"}                                                                                   Positive serology indicative for CLD: OR = 5.39 (1.87, 15.57); Biopsy-confirmed CLD: OR = 3.82 (1.04--14.07)
  [@ref15]       Addison's disease: prevalence: 2.31 per 1000 population in women with ENDO vs. 0.09 per 1000 population in general women population                                                                                                                              
  [@ref52]       ENDO risk in women with CLD: HR = 1.39 (1.14--1.70)[^\*^](#tblfn1){ref-type="table-fn"}                                                                                                                                                                          
  [@ref35]       SLE: SIR = 1.6 (1.2--2.1)[^\*^](#tblfn1){ref-type="table-fn"}; SS: SIR = 1.6 (1.3--2.0)[^\*^](#tblfn1){ref-type="table-fn"}; MS: SIR = 1.2 (1.05--1.5)[^\*^](#tblfn1){ref-type="table-fn"}                                                                       
  [@ref26]       UC: SIR = 1.5 (1.3--1.7)[^\*^](#tblfn1){ref-type="table-fn"}; CD: SIR = 1.6 (1.3--2.0)[^\*^](#tblfn1){ref-type="table-fn"}; IBD: SIR = 1.5 (1.4--1.7)[^\*^](#tblfn1){ref-type="table-fn"}                                                                        
  [@ref45]                                                                                                                                                                                                                                                                        CLD: OR = 2.80 (0.54, 14.57); any AD: OR = 1.33 (0.68, 2.60)
  [@ref56]                                                                                                                                                                                                                                                                        AD: OR = 0.90 (0.48, 1.96)
  [@ref20]       SLE: HR = 2.03 (1.17--3.51)[^\*^](#tblfn1){ref-type="table-fn"}; RA: HR = 1.41 (1.05--1.89)[^\*^](#tblfn1){ref-type="table-fn"}                                                                                                                                  
  [@ref21]       SLE: OR = 1.39 (1.09--1.78)[^\*^](#tblfn1){ref-type="table-fn"}                                                                                                                                                                                                  
  [@ref54]       Graves' disease: OR = 2.52 (1.30--4.88)[^\*^](#tblfn1){ref-type="table-fn"}; autoimmune hypothyroidism: OR = 1.61 (0.88--2.94)                                                                                                                                   All ATD: OR = 1.45 (1.10, 1.91)[^\*^](#tblfn1){ref-type="table-fn"}
  [@ref23]                                                                                                                                                                                                                                                                        Rheumatic disease: OR = 1.37 (1.28, 1.47)
  [@ref29]       Comparison of IBD disease phenotype, the use of immuno-modulators, antiTNF agents, combination therapy, and the need for IBD-related surgery                                                                                                                     
  [@ref6]                                                                                                                                                                                                                                                                         RA: OR = 1.82 (0.47, 7.02) \[control using Thonneau 1991 reference\]
  [@ref53]                                                                                                                                                                                                                                                                        SS: OR = 1.71 (1.35, 2.17)[^\*^](#tblfn1){ref-type="table-fn"}
  [@ref38]                                                                                                                                                                                                                                                                        UC: OR = 1.97 (1.67, 2.31)[^\*^](#tblfn1){ref-type="table-fn"} ; CD: OR = 2.16 (1.84, 2.55)[^\*^](#tblfn1){ref-type="table-fn"}; IBD: OR = 2.06 (1.83, 2.31)[^\*^](#tblfn1){ref-type="table-fn"}

AD, autoimmune disease; ATD, autoimmune thyroid disorder; ENDO, endometriosis; SLE, systemic lupus erythematosus; SS, Sjögren's syndrome; RA, rheumatoid arthritis; TPO, thyroid peroxidase antibody; CLD, coeliac disease; MS, multiple sclerosis; IBD, inflammatory bowel disease; CD, Crohn's disease; UC, ulcerative colitis.

^\*^Denotes *P* \< 0.05 that indicates there were significant differences between comparison groups.

###### 

**Characteristics of included studies (part 4)**.

  **Citation**   **Risk factors adjusted**                                                                                                                                                          **Temporality**
  -------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@ref16]       Age, race, parity; same hospital, same study period                                                                                                                                Investigated risk of newly diagnosed SLE in women with and without ENDO hix
  [@ref28]       ---                                                                                                                                                                                Investigated risk of ENDO in women with and without RA hix
  [@ref51]       ---                                                                                                                                                                                Investigated risk of ENDO in women with and without SLE/AD hix
  [@ref50]       ---                                                                                                                                                                                Prevalence study of AD (SLE, MS, RA, SS, thyroid disorder) in women with ENDO vs. general women population
  [@ref34]       Age, smoking status, age at last pregnancy, drug to stop lactation, age at menopause, polycystic ovary syndrome, HRT                                                               Prospective cohort study for incident RA occurred after 1987 with ENDO exposure Ø
  [@ref41]       Control matched on age                                                                                                                                                             Investigated risk of ENDO in women with and without having thyroid auto-immunity
  [@ref18]       Control matched on age, region                                                                                                                                                     Investigated risk of SS in women with and without ENDO hix
  [@ref39]       ---                                                                                                                                                                                Clinical manifestations/serological tests for women with ENDO vs. SLE vs. healthy controls; women diagnosed with ENDO by laparoscopy after SLE diagnosis was identified as ENDO cases
  [@ref40]       ---                                                                                                                                                                                Investigated risk of ENDO in women with and without thyroid disorder
  [@ref10]       Age, sex                                                                                                                                                                           Cross-sectional study of ADs prevalence (ENDO listed as an AD)
  [@ref31]       ---                                                                                                                                                                                Investigated risk of SLE, SS in women with and without ENDO hix and risk of ENDO in women with and without AD hix
  [@ref1]        Control from same city                                                                                                                                                             Investigated risk of ENDO in women with and without CLD hix
  [@ref15]       ---                                                                                                                                                                                Prevalence study of Addison's disease in women with ENDO hix vs. general women population
  [@ref52]       Control matched on age, county, period                                                                                                                                             Prospective cohort study for incident ENDO in women with and without CLD hix Ø; excluded cases with ENDO diagnosis before CLD diagnosis
  [@ref35]       Control matched on age, period                                                                                                                                                     Prospective cohort study for incident SLE, SS, MS in women with and without ENDO hix vs. general women population; women diagnosed with AD before ENDO diagnosis was excluded Ø
  [@ref26]       Control matched on age, period                                                                                                                                                     Prospective cohort study for incident IBD in women with and without ENDO hix Ø
  [@ref45]       ---                                                                                                                                                                                Investigated risk of ENDO in women with and without CLD hix
  [@ref56]       ---                                                                                                                                                                                Investigated risk of ENDO in women with and without AD hix
  [@ref20]       Age at menarche, parity, menstrual cycle length, BMI, physical activity, smoking, OCP, ethnicity, infertility and analgesic use. For RA plus parity, duration of breast feeding.   Prospective cohort study for incident SLE, RA in women with and without ENDO hix Ø
  [@ref21]       Control matched on age, county                                                                                                                                                     Investigated risk of SLE in women with and without ENDO hix; selected SLE diagnosis after ENDO diagnosis
  [@ref54]       Control matched on age, sampling year, sampling weight                                                                                                                             Prevalence study of ATD in women with and without ENDO hix
  [@ref23]       Matched controls (not specified)                                                                                                                                                   Investigated risk of ENDO in women with and without rheumatoid disease hix
  [@ref29]       Control matched on age                                                                                                                                                             Clinical manifestation, prognosis, and treatment comparing women with IBD and ENDO vs. women with IBD but without ENDO
  [@ref6]        ---                                                                                                                                                                                Prevalence study of ENDO in women with RA vs. general women
  [@ref53]                                                                                                                                                                                          Case--control study for risk of ENDO in relation to SS hix SS
  [@ref38]                                                                                                                                                                                          Investigated risk of IBD at pregnancies in women with and without ENDO hix

AD, autoimmune disease; ATD, autoimmune thyroid disorder; ENDO, endometriosis; OCP, oral contraceptive pill; SLE, systemic lupus erythematosus; SS, Sjögren's syndrome; RA, rheumatoid arthritis; CLD, coeliac disease; MS, multiple sclerosis; IBD, inflammatory bowel disease; HRT, hormone replacement therapy.

Ø Denotes studies that addressed disease diagnosis time during data analysis.

###### 

**Quality assessment for each study outcome under review (part 1)**.

  **Study outcome**   **No. of studies**   **GRADE score**   **Study design**   **Risk of bias**   **Inconsistency**                                                                                                                                                               
  ------------------- -------------------- ----------------- ------------------ ------------------ ------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------- --- -------------------------------------------
  ENDO and SLE        Eight                LOW               2                  Low, non-RCT       −1                  Four studies with high risk of bias (self-reported outcomes, small sample size, unrepresentativeness of the control group or whole study population)    0   All studies showed a positive association
  ENDO and SS         Six                  VERY LOW          2                  Low, non-RCT       −1                  Three studies with high risk of bias (self-reported outcomes, small sample size, unrepresentativeness of the control group or whole study population)   0   All studies showed a positive association
  ENDO and RA         Five                 LOW               2                  Low, non-RCT       0                   Three studies with high risk of bias (self-reported outcomes, small sample size, unrepresentativeness of the control group or whole study population)   0   All studies showed a positive association
  ENDO and ATD        Four                 VERY LOW          2                  Low, non-RCT       0                   Two studies with higher risk of bias (self-reported outcomes, small sample size, unrepresentativeness of the control group)                             0   All studies showed a positive association
  ENDO and CLD        Four                 VERY LOW          2                  Low, non-RCT       −1                  Two studies with high risk of bias (self-reported outcomes, small sample size, unrepresentativeness of the control group)                               0   All studies showed a positive association
  ENDO and MS         Three                VERY LOW          2                  Low, non-RCT       −1                  One study with high risk of bias (self-reported outcomes, small sample size, unrepresentativeness of the control group)                                 0   All studies showed a positive association
  ENDO and IBD        Four                 VERY LOW          2                  Low, non-RCT       −1                  One study with high risk of bias (small sample size, unrepresentativeness of the control group)                                                         0   All studies showed a positive association

ATD, autoimmune thyroid disorder; CLD, celiac disease; ENDO, endometriosis; IBD, inflammatory bowel disease; MS, multiple sclerosis; RA, rheumatoid arthritis; SLE, systemic lupus evythmatosus; SS, Sjögren's syndrome.

For the reported autoimmune diseases, one group ([@ref10]) conducted a nationwide cross-sectional study in Denmark estimating the prevalence and pairwise comparison of 31 autoimmune diseases (endometriosis was also listed as one of the autoimmune diseases under study). Furthermore, nine (34.6%) studies reported on SLE, six (23.1%) on SS, five (19.2%) on RA, four (15.4%) on autoimmune thyroid disorders (ATDs), four (15.4%) on IBD, four (15.4%) on CLD, three (11.5%) on MS, one on Addison's disease ([@ref15]), and one reported on rheumatic disease ([@ref23]).

Ascertainment of cases and controls {#sec12}
-----------------------------------

For ascertainment of endometriosis, 5 studies were based on self-reported data, 1 was based on self-reported data validated by hospital records in some of the study participants, and 20 were based on hospital records, among which 6 studies further confirmed endometriosis diagnosed by surgery and/or histology ([Table I](#TB1){ref-type="table"}). There were four studies which categorized endometriosis diagnosis by the Revised American Society for Reproductive Medicine classification of endometriosis ([@ref2]) into Stage I/II vs. Stage III/IV endometriosis. For ascertainment of autoimmune diseases, 6 studies were based on self-reported data and 2 were based on self-reported data validated by hospital records in some of the study participants, while for 18 studies, the disease ascertainment were based on hospital records ([Table II](#TB2){ref-type="table"}).

Two (7.7%) studies used prevalence statistics from the general female population identified from the literature as comparison group. Two (7.7%) studies used age- and period-specific incident rates identified from national statistics as risk estimates for comparison group, while eight (30.7%) studies identified female controls from nationwide registers. Seven (26.9%) studies selected controls and cases from the same region/or hospital. [@ref28] used friend controls of recruited endometriosis patients. [@ref29] compared women diagnosed with both endometriosis and IBD and compared them to women with IBD but without endometriosis matched by age and IBD type. The other five (19.2%) studies recruited women who attended obstetric/gynaecological clinics or a family planning unit.

Of all the included studies, seven (26.9%) took measures to address the temporal sequence for diagnosis of endometriosis and autoimmune diseases while six of the studies looked at incidence of autoimmune diseases after diagnosis of endometriosis, and one study looked at incidental endometriosis after diagnosis of autoimmune diseases ([Table IV](#TB4){ref-type="table"}). With regard to sample size, 5 (19.2%) studies had small sample size (≤100), 10 (38.5%) had a moderate sample size (100--1000), and 11 (42.3%) had a large sample size (≥1000). Among the 11 studies that had a large sample size (≥1000), 4 studies reported a large effect (OR/RR/SIR/HR ≥ 2) for the association between endometriosis and autoimmune diseases. As for adjustments of confounding factors or stratum-specific evaluation of effect modifiers or interactions in estimating risks, 3 (11.5%) studies included comprehensive adjustment for factors such as age, residence location, hormonal factors, or other potential confounding health conditions, 12 (46.2%) studies had made some adjustments of confounding factors such as age, sampling year, location of residence, and the other 11 (42.3%) studies did not adjust for any confounding factors ([Table IV](#TB4){ref-type="table"}).

Quality of evidence {#sec13}
-------------------

Assessment of the risk of bias and quality of the evidence of included studies was conducted based on GRADE criteria ([@ref17]) ([Tables V](#TB5){ref-type="table"} and [VI](#TB6){ref-type="table"}). Quality assessment was carried out for each study outcome (a specific autoimmune disease reported to be in association with endometriosis) if the outcome was reported by at least three studies. The quality of the evidence for each reported autoimmune disease generally received a score of 'LOW' or 'VERY LOW' by GRADE criteria ([@ref17]) due to potential risk of bias in their study design such as self-reported outcomes, cross-sectional study design, small sample size, unrepresentativeness of the control group or whole study population, limited or no adjustment of confounding factors, and reporting no CIs for risk estimates ([Table V](#TB5){ref-type="table"}). Only 5 of the 26 studies under review ([@ref34]; [@ref52]; [@ref35]; [@ref26]; [@ref20]) could provide high-quality evidence, and 4 of the studies ([@ref52]; [@ref35]; [@ref26]; [@ref20]) supported a significant association between endometriosis and SLE, SS, RA, CLD, MS, and IBD.

###### 

**Quality assessment for each study outcome under review (part 2)**.

  **Study outcome**   **Indirectness**   **Imprecision**                                 **Publication bias**   **Uplifting factors**                                             
  ------------------- ------------------ ----------------------------------------------- ---------------------- --------------------------------------------------- --- ----- --- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ENDO and SLE        0                  One study explored indirect association         −1                     Four studies with wide CIs or didn't report a CI    0   ---   2   Three studies reported large effect; two other studies with good adjustment for confounders and large sample size
  ENDO and SS         0                  All studies explored the association directly   −1                     Four studies with wide CIs or didn't report a CI    0   ---   2   Three studies with higher degree of quality: large sample size, adequate disease ascertainment, ability to approach temporality, including one study with good adjustment for potential confounders
  ENDO and RA         0                  All studies explored the association directly   −1                     Three studies with wide CIs or didn't report a CI   0   ---   2   One study reported large effect; two other studies with good adjustment for confounders and large sample size, adequate disease ascertainment, with one study with ability to approach temporality
  ENDO and ATD        0                  All studies explored the association directly   −2                     Three studies with wide CIs or didn't report a CI   0   ---   0   ---
  ENDO and CLD        0                  All studies explored the association directly   −2                     Three studies with wide CIs or didn't report a CI   0   ---   1   One study with higher degree of quality: large sample size, adequate disease ascertainment, ability to approach temporality
  ENDO and MS         0                  All studies explored the association directly   −2                     Two studies with wide CIs or didn't report a CI     0   ---   1   One study with higher degree of quality: large sample size, adequate disease ascertainment, ability to approach temporality, good adjustment for potential confounders
  ENDO and IBD        −1                 One study explored an indirect association      −1                     One study didn't report a CI                        0   ---   1   One study with higher degree of quality: large sample size, adequate disease ascertainment, ability to approach temporality

ATD, autoimmune thyroid disorder; CI, confidence interval; CLD, celiac disease; ENDO, endometriosis; IBD, inflammatory bowel disease; MS, multiple sclerosis; RA, rheumatoid arthritis; SLE, systemic lupus evythmatosus; SS, Sjögren's syndrome.

Data synthesis and meta-analysis {#sec14}
--------------------------------

Of the 26 studies in this systematic review, [@ref10] conducted a nationwide cross-sectional study in Denmark using hospital record data to estimate the prevalence and pairwise comparison of 31 autoimmune diseases (endometriosis was also listed as an autoimmune disease). In this study, women with endometriosis were found to have a greater risk of 28 autoimmune diseases including SLE, CLD, and MS in comparison to the general Danish female population; however, the associated CIs of ORs were not reported in the article, hence providing limited evidence. The following paragraphs discuss the other epidemiological studies excluding [@ref10], which reported on an association between endometriosis and autoimmune diseases ([Table III](#TB3){ref-type="table"}).

### SLE {#sec15}

[@ref50] reported, in a cross-sectional study of 3680 US women, a significantly higher prevalence of SLE in women with endometriosis in comparison to the general US female population (prevalence OR = 20.7 (95% CI: 14.3--29.9), *P* \< 0.001). This exceptionally high risk estimate is probably accounted by the self-reported nature of disease ascertainment from the study participants who were probably very conscious of the health impact of endometriosis as they were all recruited from an endometriosis patient association. [@ref51] conducted a small case--control study in 22 women with endometriosis vs. 185 control women with uterine fibroids and found that SLE prevalence was higher in women with endometriosis (SLE prevalence: 9.09% vs. 0% in women with endometriosis vs. fibroids). However, it should be noted that women with endometriosis have been found to be at a significantly increased risk of uterine fibroids ([@ref14]), and considering the small sample size of this study, this study was heavily biased. Meta-analysis of three case--control studies ([@ref16]; [@ref31]; [@ref21]) and two cohort studies ([@ref35]; [@ref20]) has shown a significantly greater risk of SLE in women with endometriosis compared to control or comparison women (OR for case--control studies: 1.36 (95% CI: 1.07--1.73), *P* = 0.010, *I^2^* = 49%; RR for cohort studies: 1.74 (95% CI: 1.10--2.77), *P* = 0.020, *I^2^* = 0%) ([Fig. 2a](#f2){ref-type="fig"}). Among these five studies in the meta-analysis, two case--control studies ([@ref16]; [@ref31]) had a high risk of bias in their study design and a small sample size; the other single case--control study and the two cohort studies ([@ref35]; [@ref20],[@ref21]) were of high quality because of their large size and appropriate adjustment for confounders. When restricting to these three studies of high quality, their results were consistent in demonstrating a statistically significant association between SLE and endometriosis with low heterogeneity in magnitude of effect. Finally, [@ref39] compared musculoskeletal and serum immunologic abnormalities in a cross-sectional study comparing three groups of women with endometriosis vs. SLE vs. healthy controls recruited from a hospital in Brazil, but did not find any noticeable similarities among these women, possibly because of the indirect study approach and small sample size.

![**Forest plots of studies.** (**A**) studies of ENDO and SLE (i.e. event); (**B**) studies of ENDO and SS (i.e. event).](dmz014f2ab){#f2}

![**Continued: Forest plots of studies.** (**C**) studies of ENDO and RA (i.e. event); (**D**) studies of ENDO and ATD (i.e. event); (**E**) studies of ENDO and CLD (i.e. event).](dmz014f2cde){#f2a}

### SS {#sec16}

[@ref50] reported, in a cross-sectional study of US women, a greater risk of SS in women with endometriosis in comparison to the general US female population (prevalence OR = 23.9 (95% CI: 15.5--36.5), *P* \< 0.001); however, as discussed above, there was a high risk of bias in their study design. Meta-analysis of three case--control studies ([@ref18]; [@ref31]; [@ref53]) conducted in Norway, Spain, and Taiwan revealed a 76% greater odds of SS in association with endometriosis (OR = 1.76 (95% CI: 1.39--2.21), *P* \< 0.001, *I^2^* = 0%) ([Fig. 2b](#f2){ref-type="fig"}). This greater odds of SS in association with endometriosis was also observed in the previously mentioned retrospective cohort study ([@ref35]) that followed up 37 661 Danish women through hospital systems (SIR = 1.6 (95% CI: 1.3--2.0), *P* \< 0.001).

### RA {#sec17}

Meta-analysis of two cross-sectional studies by [@ref50] and by [@ref6] reported a significantly increased RA risk in women with endometriosis in comparison to the general female population (OR = 1.50 (95% CI: 1.18--1.91), *P* = 0.002, *I^2^* = 0%) ([Fig. 2c](#f2){ref-type="fig"}). Yet the poor quality for these two studies should be noted. However, in a case--control study ([@ref28]), the greater odds for endometriosis in women with and without RA history was largely insignificant with a wide CI (OR = 3.07 (95% CI: 0.12, 77.50), *P* = 0.46) probably due to its small sample size (43 vs. 43 women with and without endometriosis history). Meta-analysis of two prospective cohort studies ([@ref34]; [@ref20]) also suggested a greater rate of RA among women with endometriosis, but this estimate was not statistically significant (RR = 1.46 (95% CI: 0.70--3.03), *P* = 0.31, *I^2^* = 0%) ([Fig. 2c](#f2){ref-type="fig"}) possibly due to the small sample size and wide CIs in the study conducted by [@ref34] as the risk estimate in the study by [@ref20] was significant.

### ATD {#sec18}

Meta-analysis of three case--control studies ([@ref41]; [@ref40]; [@ref54]) showed an increased risk of ATD in women with endometriosis, but this risk estimate was not significant with a wide CI and a high *I^2^* for heterogeneity (OR = 1.36 (95% CI: 0.54, 3.45), *P* = 0.52, *I^2^* = 83%) ([Fig. 2d](#f2){ref-type="fig"}). The quality of evidence provided by the meta-analysis was low, since two of the studies ([@ref41]; [@ref40]) had a higher risk of bias in their study design for having a small sample size and unrepresentative control selection, while the other study ([@ref54]) was implemented with large study population (a cross-sectional study in 5615 Korean women with endometriosis history) but were with no adjustment for confounders and thus there was a high risk for bias.

### CLD {#sec19}

A greater odds of CLD was reported to be associated with endometriosis in two case--control studies (OR by meta-analysis: 4.04 (95% CI: 1.53--10.65), *P* = 0.005, *I^2^* = 0% ([@ref1]; [@ref45]) ([Fig. 2e](#f2){ref-type="fig"}). However, these two studies had small sample sizes and wide CIs in risk estimates. Yet in a large retrospective cohort study by [@ref52] that followed up 11 097 Swedish women who had CLD biopsy for endometriosis incidence in comparison to healthy female controls ([@ref52]), endometriosis was found to be significantly associated with CLD (HR = 1.39 (95% CI: 1.14--1.70), *P* \< 0.001).

### MS {#sec20}

For MS and endometriosis, the cross-sectional study by [@ref50] reported a 7-fold greater prevalence for MS in women with endometriosis in comparison to the general female population (prevalence OR = 7.1 (95% CI: 4.4--11.3), *P* \< 0.001). However, the issue of selective study population and wide CIs in the study by [@ref50] has been discussed. Nevertheless, in the retrospective cohort study by [@ref35], a 20% greater risk for MS was observed in 37 661 Danish women with hospital-diagnosed endometriosis in comparison to general female controls (SIR = 1.2 (95% CI: 1.1--1.5), *P* \< 0.001).

### IBD {#sec21}

[@ref38] conducted a case--control study in 14 279 Danish women with IBD at time of conception and 1 832 732 women without IBD at conception based on hospital records during 1994--2015 and found an increased risk of pregnant women with IBD in women with endometriosis history (UC: OR = 1.97 (95% CI: 1.67--2.31); CD: OR = 2.16 (95% CI: 1.84--2.55); IBD: OR = 2.06 (95% CI: 1.83--2.31), *P* \< 0.001). Also, an earlier cohort study ([@ref26]) during 1977--2007 using hospital records in Danish women reported a significantly increased incidence of IBD in women with endometriosis history in comparison with women without known endometriosis (UC: SIR = 1.5 (95% CI: 1.3--1.7); CD: SIR = 1.6 (95% CI: 1.3--2.0); IBD: SIR = 1.5 (95% CI: 1.4--1.7), *P* \< 0.001). The two studies in Danish women using hospital records during two different periods provided higher quality evidence for an association between endometriosis and IBD due to their large sample size, hospital-based disease ascertainment, and the ability to approach temporality between IBD and endometriosis. [@ref29] studied endometriosis and IBD with an indirect approach by comparing the IBD phenotype, prognosis, treatments among women with IBD and with or without co-morbid endometriosis, and no significant difference between two groups were found except a slightly higher rate of bowel strictures in women with both IBD and endometriosis. However, this indirect approach by [@ref29] and their small sample size (51 women with IBD and endometriosis vs. 102 women with IBD alone) should be noted.

### Other autoimmune diseases {#sec22}

In addition, [@ref15] reported, in a cross-sectional study, that the prevalence of Addison's disease in US women with endometriosis was higher than the general US females (2.31 per 1000 population vs. 0.09 per 1000 population), but these prevalence estimates were too low to generate meaningful risk estimates for the studied association. [@ref23] in their retrospective cohort study following up 55 000 Taiwanese women through hospital systems described an increased risk of rheumatic diseases in women with endometriosis (OR = 1.37 (95% CI: 1.28--1.47), *P* \< 0.001) compared to the general female population. Although rheumatic diseases were often recognized as autoimmune diseases such as SLE, SS, and RA, they did not specify which kind of rheumatic diseases were studied.

Sensitivity analysis {#sec23}
--------------------

A sensitivity analysis for each meta-analysis with at least three studies was conducted. Within each meta-analysis, each study was taken out respectively to assess for its influence on the overall risk estimates.

The high heterogeneity in the meta-analysis for studies on SLE risk or SS risk in women with and without endometriosis history is accounted by the study by [@ref31]. In the meta-analysis of three case--control studies ([@ref41]; [@ref40]; [@ref54]) for endometriosis risk in women with and without ATD, each study seemed to account for the high heterogeneity (*I^2^* = 83%).

For meta-analysis with an *I^2^* = 0% (which indicates there is no evidence of heterogeneity), a fixed-effect model was used for meta-analysis. As the random-effect estimates and fixed-effect estimates would provide different meta-analysis results because of giving different weight to each studies when *I^2^* \> 0% with evidence of heterogeneity, a switch between random-effect estimate and fixed-effect estimate for each meta-analysis was performed to assess for small-study effects, since the included studies in the random-effects meta-analysis, especially small studies, would be weighted relatively more equally than a fixed-effect analysis in the presence of heterogeneity indicated by *I^2^* more than 0%.

A switch from a fixed-effect model to a random-effect model for the meta-analysis of three case--control studies for SLE risk in women with and without endometriosis history, the pooled OR became largely insignificant (OR = 1.24, 95% CI: 0.59--2.62, *P* = 0.59) with more weighing towards smaller studies. For the meta-analysis of three case--control studies for endometriosis risk in women with ATD history in comparison to those without, a switch from a random-effect model to a fixed-effect model to weight down for smaller studies, the pooled OR became significant with a *P*-value equals to 0.04 (OR = 1.31, 95% CI: 1.02--1.68).

Discussion {#sec24}
==========

In this systematic review of 26 population-based cross-sectional, cohort, and case--control studies, endometriosis was suggested to be associated with a range of autoimmune diseases including SLE, SS, RA, ATD, CLD, MS, IBD, and Addison's disease, but the quality of the evidence for each reported autoimmune disease in association with endometriosis generally received a score of 'LOW' or 'VERY LOW' by GRADE criteria ([@ref17]) due to potential risk of bias in their study design. Only 4 of the 26 studies under review ([@ref52]; [@ref35]; [@ref26]; [@ref20]) could provide high-quality evidence to support for a significant association between endometriosis and SLE, SS, RA, CLD, MS, and IBD.

While there are a number of review articles on the (auto)immunity of endometriosis, these articles mostly discuss the biological or immunological aspects of endometriosis. This systematic review, however, is the first review amalgamating the evidence from available population-based studies with a focus on the association between endometriosis and autoimmune diseases. Our review benefits from a comprehensive search strategy including 23 most common autoimmune diseases (i.e. with a prevalence rate ≥10 per 100 000 people worldwide identified by [@ref22]) occurring with endometriosis. As a result, we were able to identify 18 additional population-based studies compared to 8 studies previously included in a review investigating of risk of chronic disease in endometriosis patients ([@ref27]). Moreover, the current review captures several large-scale and well-designed studies with six studies reporting a significant association between endometriosis and autoimmune diseases. Furthermore, meta-analyses were conducted to better evaluate the overall evidence for association of endometriosis and autoimmune disease risks. The meta-analyses were designed carefully with strict subgroup analysis of study results from cross-sectional, case--control, or cohort studies. Sensitivity analyses were conducted to examine robustness of the meta-analysis results.

However, some limitations in this review or in the included studies should be noted. The GRADE score for quality assessment for each study outcome were either 'LOW' or 'VERY LOW'. Many of the included studies were small in size and had limited number of endometriosis and/or autoimmune cases, presenting a high possibility to generate spurious associations. Also, because of the limited statistical power of studies with small samples size included in a meta-analysis, a random-effect estimate would weigh more towards the small studies, thus neutralizing a significant association found in large and well-conducted studies.

Another issue is the difficulty in establishing the temporality between endometriosis and autoimmune diseases, that is, to determine the order of disease development and presentation, and a potential causal relationship or whether they share the same pathophysiology. In cross-sectional and case--control studies, a temporal relationship between these two conditions was impossible to address because the design of the incorporated studies did not include time of diagnosis. However, prospective cohort studies that follow up people with certain exposure(s) prior to occurrence of the health outcome of interest could provide better evidence on temporality. Moreover, there is an estimated average delay of 7 years between onset of endometriosis-associated symptoms and its diagnosis ([@ref37]). In addition, some autoimmune diseases such as CLD could remain undetected for years, thus posing a greater challenge in defining the accurate time of disease onset in order to establish the temporal sequence between the two.

In addition, the cross-sectional and case--control studies might be biased because of suboptimal control selection. For example, [@ref28] recruited friends of endometriosis patients as endometriosis-free controls. Friend controls might have biased the association under study since friends are more likely to share similar lifestyles or come from the same socio-economic status that could have influenced their health outcomes and likelihood of valid diagnoses. [@ref51] recruited women from hospital records diagnosed with fibroids confirmed by hysterectomy as controls for women with endometriosis but fibroids and endometriosis are correlated diseases ([@ref55]). Other studies recruited women who attended obstetrical/gynaecological clinics or family planning units as endometriosis-free controls, but since endometriosis is a gynaecological disorder, if these women have sought help for obstetric or gynaecological reasons, there exists a risk that their health conditions might be potentially associated with endometriosis.

In order to generate the best evidence, we recommend future population-based studies to further investigate the association between endometriosis and autoimmune diseases by adopting a prospective cohort study approach with long follow-up time, large study populations, strict disease ascertainment based on hospital diagnosis records (preferably surgical diagnosis for endometriosis and biomarker tests for certain autoimmune disease), carefully selected disease-free controls, and good adjustment for potential confounding factors. Genome-wide association study for endometriosis and autoimmune diseases may help to establish a potential causal relationship between the two.

Possible explanations for the observed association between endometriosis and autoimmune diseases {#sec25}
------------------------------------------------------------------------------------------------

While the aetiology of endometriosis is largely unknown, the most widely accepted hypothesis for the pathogenesis of endometriosis is the retrograde menstruation theory proposing the pelvic dissemination of endometrial cells through the uterine tubes ([@ref44]). However, as retrograde menstruation is present in almost all women ([@ref19]), and only a proportion of women develop endometriosis, other causes including aberrations in the immune system of endometriosis patients have been proposed ([@ref55]), preventing clearance of ectopic endometrial cells and allowing for their implantation, survival, and maintenance outside the uterus ([@ref7]).

Many studies have investigated the (auto)immunological pathology of endometriosis; however, there is little understanding of shared biological pathways between endometriosis and autoimmune diseases that would explain an increased comorbidity. Studies have shown an escape of cells from immune surveillance by analysing peritoneal environment in endometriosis ([@ref48]). Abnormalities in almost all types of immune cells have been identified, including increased levels of peritoneal neutrophils and macrophages, reduced cytotoxic function of natural killer cells, and aberrant numbers of T and B lymphocytes that aid endometriotic cell growth, maintenance, invasion, and angiogenesis ([@ref25]). Moreover, there is evidence of increased levels of a range of autoantibodies in women with endometriosis, spurring enthusiasm among researchers to investigate their potential role as biomarkers for endometriosis. A recent series of Cochrane reviews on blood biomarkers and urinary biomarkers for endometriosis found that although several antibodies have been indicated to be increased in women with endometriosis, only anti-endometrial antibodies and interleukin-6 were found to be useful for detecting endometriosis but their accuracy still cannot replace the standard surgical diagnosis ([@ref30]; [@ref36]), supporting earlier systematic reviews ([@ref32], [@ref33]) and clinical guidelines ([@ref9]).

As endometriosis is a highly heritable disease, a number of candidate gene studies of endometriosis have been conducted to investigate the association between autoimmune-related genes and endometriosis ([@ref5]). Among these studies, genes such as PTPN22 that have been well established to be associated with RA have also been reported to be associated with endometriosis in comparison to endometriosis-free controls. Also, HLA alleles that are most commonly associated with autoimmune diseases have also been reported to be associated with endometriosis. However, these studies have generally included small sample sizes, poorly defined ethnicity and limited genotyping of loci. Importantly, these autoimmune-related genes were not reported in robust, large-scale genome-wide association studies of endometriosis ([@ref46]).

Finally, while endometriosis is an oestrogen-dependent disorder, hormonal factors have also been found to play an important role to increase the activity or severity of autoimmune diseases. For example, a study of 16 patients with relapsing--remitting MS found that assisted reproduction technology for infertility treatment using gonadotropin-releasing hormone agonists and recombinant FSH was associated with a 7-fold increase in risk of MS exacerbation ([@ref8]).

Conclusions and clinical implications {#sec26}
-------------------------------------

Evidence from our systematic review of observational population-based studies suggests an increased risk of comorbidity of autoimmune diseases including SLE, SS, RA, ATD, CLD, MS, IBD, and Addison's disease. However, although there were a few high-quality, well-designed studies with large sample size, many of the included studies in this review were of low quality and had limitations. It is important to note that the evidence did not allow for accurate estimation of increased risk and have no clinical diagnostic utility. As most studies of endometriosis include women of reproductive age, longer follow-up studies are needed to ascertain the true risk of autoimmune diseases that may occur after menopause. Larger follow-up studies would also help understand whether endometriosis is a risk factor or a consequence of autoimmune diseases or if these two types of disorders share pathological mechanism and pathways resulting in their co-occurrence.

The observational evidence also does not exclude the possibility that selection and diagnostic biases in the studies underlie some of the associations observe, nor was there any evidence that the observed associations are biologically underpinned. Further studies are needed to explore the latter. Genetic and biological and studies of immunological dysfunctions in the context of endometriosis may improve our understanding of the pathogenesis of both conditions, and if shared pathogenic origins are observed, contribute to the identification of novel therapeutic and diagnostic targets.
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